Pathology & Oncology Research

, Volume 13, Issue 2, pp 114–122 | Cite as

Lineage-specific clonality analysis of chronic myeloproliferative disorders and myelodysplastic syndrome by human androgen receptor assay

  • Pál Jáksó
  • László Kereskai
  • Lenke Molnár
  • László Pajor


In myelodysplastic syndrome (MDS) as well as chronic myeloproliferative disorders (CMPD) others than chronic myeloid leukemia the frequency of pathognomonic genetic aberrations is very low and, therefore, X chromosome inactivation (XI) assays may help in assessing the clonality. To establish specific clonality criteria on XI, human androgen receptor assay (HUMARA) was performed on sorted myeloid and lymphoid peripheral blood cells of 21 healthy females. Clonality criteria 1 and 2 conferring at least 90% specificity were set based on the ranges and differences of XI number (XIN) describing the ratio of representation of the two alleles in as well as in between reactive myeloid and lymphoid compartments. Spiking experiments indicated that the test identifies clonality reliably when no more than 40–50% reactive cells are admixed. In the CMPD and MDS cases peripheral myeloid cells were monoclonal by one of the two criteria in 71–100%, whereas lymphoid cells in 28–75%. The results of HUMARA, available in 73% of the female patients, supported the clinicopathological data in 84% as well as proved pluripotent stem cell origin in 31–75% and 21% of CMPDs and MDS, respectively.

Key words

chronic myeloproliferative disease myelodysplasia HUMARA 



chronic lymphocytic leukemia


chronic myeloid leukemia


chronic myeloproliferative disorder


essential thrombocytemia


hypereosinophilic syndrome


myelodysplastic syndrome


non-random Xinactivation


polymorphic microsatellite region


polycythemia vera




X-inactivation number


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allen RC, Zoghbi HY, Moseley AB: Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229–1239, 1992PubMedGoogle Scholar
  2. 2.
    Anderson JE, Gilliland DG, List AF: Myelodysplastic syndrome. Educational Materials by the American Society of Hematology, 1998Google Scholar
  3. 3.
    Baxter EJ, Scott LM, Campbell PJ: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061, 2005PubMedGoogle Scholar
  4. 4.
    Busque L, Gilliland DG: X-inactivation analysis in the 1990s: promise and potential problems. Leukemia 12:128–135, 1998CrossRefGoogle Scholar
  5. 5.
    Culligan DJ, Cachia P, Wittaker J: Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81:346–352, 1992PubMedCrossRefGoogle Scholar
  6. 6.
    Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 340:1649–1660, 1999PubMedCrossRefGoogle Scholar
  7. 7.
    Hellström-Lindberg E, Willmann C, Barrett AJ: Achievements in understanding and treatment of myelodysplastic syndromes. Educational Materials by the American Society of Hematology, 2000.Google Scholar
  8. 8.
    Jaffe ES, Harris NL, Stein H, Vardinian JW eds. World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001Google Scholar
  9. 9.
    James C, Ugo V Le Couedic JP: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148, 2005PubMedCrossRefGoogle Scholar
  10. 10.
    Knuutila S, Teerenhovi L, Larramendy ML: Cell lineage involvement of recurrent chromosomal abnormalities in hematological neoplasms. Genes, Chromosomes Cancer 10:95–102, 1994PubMedCrossRefGoogle Scholar
  11. 11.
    Kralovics R, Passamonti F, Buser AS: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790, 2005PubMedCrossRefGoogle Scholar
  12. 12.
    Levine RL, Wadleigh M, Cools J: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397, 2005PubMedCrossRefGoogle Scholar
  13. 13.
    Nilsson L, Åstrand-Grundström I: Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 156:2012–2021, 2000Google Scholar
  14. 14.
    Pajor L, Matolcsy A, Vass JA, Méhes G, Marton É, Szabó F: Phenotypic and genotypic analyses of blastic cell population suggest that pure B-lymphoblastic leukemia may arise from myelodysplastic syndrome. Leuk Res 22:13–17, 1998PubMedCrossRefGoogle Scholar
  15. 15.
    Pearson TC, Messinezy M, Westwood N: A Polycythemia Vera Update: diagnosis, pathobiology, and treatment. Educational Materials by the American Society of Hematology, 2000.Google Scholar
  16. 16.
    Raskind WH, Steinmann L, Najfeld V: Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia 12: 108–116, 1998PubMedCrossRefGoogle Scholar
  17. 17.
    Tonon L, Bergamaschi G, Dellavecchia C, Rosti V, Lucotti C, Malabarba: Unbalanced X-chromosome inactivation in haematopoietic cells from normal women. Br J Haematol 102:996–1003, 1998PubMedCrossRefGoogle Scholar
  18. 18.
    Zhao R, Xing S, Li Z: Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 280:22788–22792, 2005PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2007

Authors and Affiliations

  • Pál Jáksó
    • 1
  • László Kereskai
    • 1
  • Lenke Molnár
    • 2
  • László Pajor
    • 1
  1. 1.Department of Pathology, Faculty of MedicineUniversity of PécsPécsHungary
  2. 2.1st Department of Internal Medicine, Faculty of MedicineUniversity of PécsPécsHungary

Personalised recommendations